Menu Back toSession-0302-The-Feasibility-of-Initiating-Clinical-Trials-by-Single-IRB-Approving-in-China

The 7th DIA China Annual Meeting


Session 0302 The Feasibility of Initiating Clinical Trials by Single IRB Approving in China

Session Chair(s)

Shuting  LI, MD

Shuting LI, MD

  • Deputy Director
  • GCP Alliance, China, China

Opening

Speaker(s)

George  Guo

George Guo

  • Global Monitoring Operation Country Head
  • Novartis Pharmaceuticals, China
Winnie  Xu

Winnie Xu

  • AD
  • Quintiles Medical Development (Shanghai) Co. Ltd, China
Huanling  Wang

Huanling Wang

  • Vice Director, Clinical Pharmacology Research Center
  • Peking Union Medical College Hospital, China
YongChuan  Chen

What will be reviewed in multicenter ethical review units should review what?

YongChuan Chen

  • Director,Drug Clinical Trial Institute Office
  • Xinan Hospital of Army Medical University, China
Zhiqiang  Ning

Zhiqiang Ning

  • Vice President, Research & Clinical Development
  • Shenzhen Chipscreen Biosciences, Ltd., China
Tim  Shi

The feasibility of center ethical review implementation in China

Tim Shi

  • Executive Director
  • GlobalMD, United States

Contact us

For exhibition, advertising and hosting inquiry, please contact:
Jean XU: jxu@kellencompany.com, or Sofie Peeters: speeters@kellencompany.com
Tel: +86 10 5923 1096

For general inquiry, please contact DIA China office:
dia@diachina.org
Tel: +86 10 5704 2650